Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes

11. november 2026 opdateret af: Novo Nordisk A/S

Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes

The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

36

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • Cypress, California, Forenede Stater, 90630
        • Altasciences Clinical LA, Inc.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female (sex assigned at birth, inclusive of all gender identities).
  • Age 18 and older at the time of signing the informed consent.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

For participants with type 2 diabetes (T2D)

  • Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
  • No treatment with oral anti-diabetic drugs except metformin. Treatment with metformin should be stable (dose and dosing frequency) for at least 90 days before screening.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention(s) or related products.
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
  • Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders as judged by the investigator.
  • Diagnosed with or suspected to suffer from gastroparesis, hiatal hernia or severe gastro-oesophageal reflux diseases with daily symptoms and/or when in supine position.
  • Use of other medications known to affect the motility of the stomach.
  • Inability to lie in the right lateral decubitus position for gastric ultrasonography.

For participants without T2D - Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) [48 millimoles per mole (mmol/mol)] at screening.

For participants with T2D

- HbA1c ≥ 10.5 % (91 mmol/mol) at screening.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Zenagamtide

Participants will receive zenagamtide once weekly subcutaneously (s.c.).

Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
Gastric volume after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2

Measured as milliliter per kilogram (mL/kg)

6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
Gastric volume after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2

Measured as mL/kg

6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
Presence of solids in the stomach (antrum grade 'solid') after fasting following a liquid meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-4 and V17D2
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V2D-1 and V19D2
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
Gastric volume after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5

Measured as mL/kg

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 4 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D5
Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
Gastric volume after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8

Measured as mL/kg

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8
Presence of solids in the stomach (antrum grade 'solid') after fasting following a solid, high-fat meal 7 days after dosing of s.c. zenagamtide once weekly (Yes/No)
Tidsramme: 6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8

Measured as count of participants

6, 8, 10, 12, 18 and 24 hours after start of fasting on V19D8

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

12. november 2026

Primær færdiggørelse (Anslået)

14. januar 2028

Studieafslutning (Anslået)

11. februar 2028

Datoer for studieregistrering

Først indsendt

11. november 2026

Først indsendt, der opfyldte QC-kriterier

11. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • NN9490-8698
  • U1111-1336-6870 (Anden identifikator: World Health Organization (WHO))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .